NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis $8.88 +0.24 (+2.78%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.65▼$9.3050-Day Range$5.98▼$8.8852-Week Range$3.14▼$13.70Volume413,299 shsAverage Volume706,327 shsMarket Capitalization$551.89 millionP/E RatioN/ADividend YieldN/APrice Target$15.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fulcrum Therapeutics alerts: Email Address Fulcrum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.4% Upside$15.57 Price TargetShort InterestBearish11.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 5 Articles This WeekInsider TradingSelling Shares$1,831 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.24) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector720th out of 936 stocksPharmaceutical Preparations Industry337th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFulcrum Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Fulcrum Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.68% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Fulcrum Therapeutics has recently increased by 37.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FULC. Previous Next 2.4 News and Social Media Coverage News SentimentFulcrum Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Fulcrum Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,831.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($1.24) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fulcrum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Fulcrum Therapeutics Stock (NASDAQ:FULC)Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FULC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FULC Stock News HeadlinesJuly 24 at 8:00 AM | globenewswire.comFulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ETJuly 18, 2024 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of "Buy" by AnalystsJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 21, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight RecommendationMay 16, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug ProspectsMay 14, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)May 14, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?July 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 14, 2024 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | finance.yahoo.comFulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...May 13, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | globenewswire.comFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular DystrophyMay 12, 2024 | markets.businessinsider.comHere's what to expect from Fulcrum Therapeutics's earningsMay 9, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate in Upcoming May ConferencesMay 8, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet NeurologyMay 6, 2024 | globenewswire.comFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ETSee More Headlines Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FULC CUSIPN/A CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Stock Price Target$15.57 High Stock Price Target$23.00 Low Stock Price Target$11.00 Potential Upside/Downside+75.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,330,000.00 Net Margins-3,470.05% Pretax Margin-3,961.20% Return on Equity-40.60% Return on Assets-37.19% Debt Debt-to-Equity RatioN/A Current Ratio20.38 Quick Ratio20.38 Sales & Book Value Annual Sales$2.81 million Price / Sales196.40 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book2.34Miscellaneous Outstanding Shares62,150,000Free Float59,606,000Market Cap$551.89 million OptionableOptionable Beta2.29 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Alexander C. Sapir (Age 57)CEO, President & Director Comp: $961.26kMr. Alan A. Musso C.M.A. (Age 62)CPA, Chief Financial Officer Comp: $545.1kMr. Curtis G. Oltmans J.D. (Age 61)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $585.4kMr. Mel Hayes (Age 54)Executive Vice President of Patient Experience Comp: $631.5kDr. Bradley E. Bernstein M.D.Ph.D., FounderDr. Michael R. GreenFounderDr. Rudolf Jaenisch M.D.Ph.D., FounderDr. Tsun-Huei Lee M.D. (Age 60)Ph.D., Founder Dr. Danny ReinbergFounderMr. Gregory TourangeauController & Principal Accounting OfficerMore ExecutivesKey CompetitorsOrchard TherapeuticsNASDAQ:ORTXbluebird bioNASDAQ:BLUESangamo TherapeuticsNASDAQ:SGMOKezar Life SciencesNASDAQ:KZRCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 186,727 shares on 7/26/2024Ownership: 0.300%Assenagon Asset Management S.A.Bought 497,456 shares on 7/18/2024Ownership: 0.800%SG Americas Securities LLCBought 13,887 shares on 7/12/2024Ownership: 0.042%Jane Street Group LLCBought 188,212 shares on 5/16/2024Ownership: 0.861%Jacobs Levy Equity Management Inc.Sold 101,658 shares on 5/16/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions FULC Stock Analysis - Frequently Asked Questions How have FULC shares performed this year? Fulcrum Therapeutics' stock was trading at $6.75 at the start of the year. Since then, FULC stock has increased by 31.6% and is now trading at $8.88. View the best growth stocks for 2024 here. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 40.60% and a negative net margin of 3,470.05%. When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an IPO on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' top institutional investors include Assenagon Asset Management S.A. (0.80%), Bank of New York Mellon Corp (0.30%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould and Greg Tourangeau. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV) and Xeris Biopharma (XERS). This page (NASDAQ:FULC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.